D&D Pharmatech begins Phase 2 trial for DD01, a long-lasting dual GLP-1/Glucagon receptor agonist, to assess its safety and efficacy in overweight/obese individuals with MASLD/MASH.

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) has had its second NDA accepted by NPMA for locally advanced or metastatic EGFR-mutant NSCLC.

IGC Pharma Broadens Medication Range to Include Metabolic Diseases with IGC-1A, a Possible New GLP-1 Agonist.

Azitra Reveals Initial Patient Screening and Enrollment Plans for Phase 1b ATR-12 Trial in Netherton Syndrome.

Innovo Therapeutics Inc. Unveils Phase 2 Clinical Data Highlighting the Breakthrough Effectiveness of INV-001 for Post-Thyroidectomy Scar Treatment.

The U.S. has approved RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) as an initial treatment without chemotherapy for patients with advanced lung cancer and EGFR mutations.

Sonnet BioTherapeutics Signs Clinical Collaboration for Investigator-Led, Funded Phase 1/2a Trial of SON-1210 with Chemotherapy in Pancreatic Cancer.

China's NMPA Grants Approval for PADCEV™ (Enfortumab Vedotin) to Treat Advanced or Metastatic Urothelial Cancer.

TEPKINLY® (epcoritamab) Gains Another European Commission Nod for Adult Relapsed/Refractory Follicular Lymphoma Treatment.

The U.S. FDA has removed the partial clinical hold previously imposed on MediLink Therapeutics' (Suzhou) Co., Ltd. Phase I trial, which is assessing BNT326/YL202 (NCT05653752) and was disclosed on June 17, 2024.

Apogee Therapeutics Starts Phase 1 Trial for APG990, a New Long-Lasting OX40L Antibody for Atopic Dermatitis and Inflammatory Diseases, with Initial Participants Dosed.

ImmuneSensor Therapeutics Gains Approval from Australian Authorities to Begin First-in-Human Phase 1 Trial for cGAS Inhibitor Drug IMSB301.